sunresin(SZ:300487) Xin Lang Cai Jing·2025-10-26 00:36Core Viewpoint - The company has achieved record-high gross margins, but short-term profits are impacted by foreign exchange losses and tax payments, maintaining a "Buy" rating [1] Group 1: Financial Performance - In the first three quarters of 2025, the company reported revenue of 1.933 billion yuan, a year-on-year increase of 2.2%, and a net profit attributable to shareholders of 652 million yuan, up 9.27% year-on-year [1] - In Q3 2025, the company achieved revenue of 686 million yuan, a year-on-year increase of 14.86% and a quarter-on-quarter increase of 2.29%; net profit attributable to shareholders was 207 million yuan, a year-on-year increase of 7.72% but a quarter-on-quarter decrease of 17.58% [1] - The comprehensive gross margin for Q3 2025 was 55.62%, an increase of 4.42 percentage points year-on-year and 3.96 percentage points quarter-on-quarter [2] Group 2: Business Segments - The life sciences segment saw a revenue increase of 11% year-on-year, while the metal resources segment grew by 30% year-on-year, and the water treatment segment increased by 9% year-on-year; the food processing sector experienced a significant growth of 50% year-on-year [2] - The company is focusing on high-margin businesses, with the polypeptide solid-phase synthesis carrier business continuing to show good growth [2] Group 3: Future Growth Prospects - The company plans to invest 1.15 billion yuan to build a high-end materials industrial park for life sciences, which is expected to support future growth [3] - The company is expanding its life sciences business domestically and establishing a global marketing and technical service network [3] - New product developments in the life sciences sector include antibody IND applications and various types of chromatography fillers, which are anticipated to become new growth points for the company [3]